| Pharmaceutical Information |
| Drug Name |
Liraglutide |
| Drug ID |
BADD_D01298 |
| Description |
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist[Label,A6932]. Liraglutide is 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34[A6932]. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor[A6932]. Liraglutide was granted FDA approval on Januray 25, 2010[L6070]. |
| Indications and Usage |
For use in/treatment of diabetes mellitus type 2. |
| Marketing Status |
Prescription |
| ATC Code |
A10BJ02 |
| DrugBank ID |
DB06655
|
| KEGG ID |
D06404
|
| MeSH ID |
D000069450
|
| PubChem ID |
16134956
|
| TTD Drug ID |
D03GOI
|
| NDC Product Code |
66558-0193; 69766-034; 0169-4060; 71796-022; 73569-007; 32861-0003; 50090-4503; 52221-122; 65129-1375; 50090-4257; 70155-003; 50090-2853; 41524-0011; 14403-0009; 76177-118; 0169-2800; 66558-0181; 0420-9006 |
| Synonyms |
Liraglutide | Victoza | Saxenda | NN 2211 | 2211, NN | NN2211 | NN-2211 |
|
| Chemical Information |
| Molecular Formula |
C172H265N43O51 |
| CAS Registry Number |
204656-20-2 |
| SMILES |
CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)
NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O
)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O
)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O
)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(
CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)
N)C(=O)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
